Key result
The optimal treatment strategy for chronic coronary disease remains debated, with ongoing discussion regarding the benefits of surgical revascularization versus optimal medical therapy.
Why the study?
Does myocardial revascularization (CABG or PCI) improve outcomes compared to optimal medical therapy in patients with chronic coronary disease?
Does myocardial revascularization (CABG or PCI) improve outcomes compared to optimal medical therapy in patients with chronic coronary disease?
Answers are grounded in this paper and cite their sources.
This editorial highlights the ongoing debate regarding the optimal treatment strategy (revascularization vs. medical therapy) for chronic coronary disease, emphasizing the need for individualized patient care and standardized surgical techniques.
The advantage of myocardial revascularization methods, both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), over optimal medical therapy (OMT) has been proven for many forms of coronary artery disease (CAD) [1]. At the same time, the fundamental challenge for cardiac surgeons is the improved results of non-interventional therapies. That is, probably why it is difficult to imagine a greater heat of passion in the scientific cardiological community than the one that unfolded around the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) study [2], which, like previous trials [Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE), Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D), Medicine, Angioplasty, or Surgery Study (MASS II), Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Versus OMT (FAME 2)], have failed to show benefits of revascularization methods over OMT in patients with chronic coronary disease (CCD). The results of the ISCHEMIA study and their interpretation received criticism, partly fair, regarding potential limitations in the study design [3–6]. For instance, the conclusions of De Luca et al. [4], based on 5070 consecutive patients, were as follows: ‘In a contemporary real-world cohort of stable CAD, only 4% of patients resulted as eligible for the ISCHEMIA. These patients presented an extremely low annual risk of adverse events, especially when compared with other groups of stable CAD patients’. De Martino et al. [7], whose manuscript is published in EJCTS, set the goal, based on their own results (353 patients), to prove the benefits of surgical revascularization in the treatment of stable ischaemic heart disease. The authors believe that if PCI is unable to improve the prognosis in patients with stable angina, then CABG can. It remains to convince the cardiologists, interventional cardiologists and, of course, the patients themselves. So, it is still necessary to choose a rational treatment strategy to deal with one of the most ‘prosperous’ categories of patients with CAD-CCD: those without left main stenosis, New York Heart Association functional class I-II, ejection fraction >35%, normal renal function and so forth). The first problem that arises is how to highlight, among the heterogeneous strata of patients with CCD and the moderate-to-severe ischaemia, those for whom surgical revascularization can provide potential benefits. Probably, in addition to stress testing, a broader use of coronary computed tomography angiography as the most cost-effective first-line test in the evaluation of stable chest pain can help [8, 9]. Let us assume that this problem is resolved. ‘Major surgery is just one of many instances when treatment can result in a failure more serious than the consequences of doing nothing’ [10]. So, should patients be offered surgery immediately, or should they be subject to ongoing monitoring, with the possibility of choosing more aggressive tactics only if the status worsens? ‘We know from previous studies that procedural myocardial infarction is associated with an increased risk of morbidity and mortality during the first year after revascularization, and this clearly explains the higher incidence of early events in the invasive strategy group’ [5]. Therefore, the philosophical question when choosing a treatment strategy comes down to the following formulation: Is the patient ready to choose the greater immediate and early postoperative risk associated with myocardial revascularization and the subsequent more favourable prognosis (in relation to cardiac events) or the somewhat worse (but, in general, comparable) long-term results, but no risk at present? In addition, most importantly, is the need to continue OMT. We agree with the point of view expressed by Arias et al. [5]: ‘The available data from randomized trials, including the ISCHEMIA trial, provide enough evidence to implement an initial OMT strategy in mildly symptomatic, low-risk patients, regardless of the degree of ischaemia on stress or exercise imaging. Around 20% to 30% of these patients will require either a PCI or CABG due to angina progression/unresponsiveness to medical therapy, non-adherence or development of an acute coronary syndrome’. In addition, when making the decision about a treatment strategy, we should not forget about the unpleasant, disturbing fact mentioned in the study by De Martino et al.: ‘Death by any cause occurred in 94 patients (27%)’. That means there is a probability of a lethal outcome in the next few years, even if it is not associated with cardiovascular events, which is very different from zero. Finally, in our opinion, one more problem lies on a completely different plane: the fact that tactical differences exist in the surgical treatment of CAD among hospitals and surgeons. To be of value, all operations should rely on the same standardized technique. Therefore, it is pertinent to question whether it is generally possible to combine in a single denominator the results for conditions treated with different approaches. Moreover, is it possible to make similar comparisons between individual cardiac surgeons? ‘A failure rate for a hospital is an average of the failure rates of the individual practitioners, and comparisons between groups will disguise still larger differences that exist between practitioners’ [10]. Each surgeon has preferences, i.e. whether to perform the intervention under cardiopulmonary bypass or on a beating heart; whether to use complete arterial revascularization (in addition to left internal mammary artery–left anterior descending artery) or vein grafting; whether to use sequential anastomoses. Therefore, it is likely that the results obtained by individual groups or centres (if not to a greater extent) do not reflect the ‘real-world’ general practice. Which of the methods (CABG, PCI, OMT or a combination) is able to provide the patient with CCD with the greatest benefits is still open for discussion. This means that it is necessary to continue both the ISCHEMIA trial and the research that substantiates the advantages and/or the disadvantages of the strategy of surgical revascularization. Let us not forget that the results of the global multicentre studies should be the ‘proof of the theorem’, without any further additional confirmation or confutation. Conflict of interest: None declared.
No takes yet. Share an insight, caveat, or question.
Travin et al. (2022) conducted an editorial in Chronic coronary disease. Surgical revascularization vs. Optimal medical therapy was evaluated. The optimal treatment strategy for chronic coronary disease remains debated, with ongoing discussion regarding the benefits of surgical revascularization versus optimal medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: